Entering text into the input field will update the search result below

Atea's oral drug bemnifosbuvir for COVID-19 gets FDA fast track status

Apr. 25, 2023 9:00 AM ETAtea Pharmaceuticals, Inc. (AVIR)By: Ravikash, SA News Editor
FDA written on wooden cube with keyboard , calculator, chart,glasses.Business concept

Iryna Drozd

  • The U.S. Food and Drug Administration (FDA) granted fast track designation to Atea Pharmaceuticals' (NASDAQ:AVIR) bemnifosbuvir to treat COVID-19.
  • The oral antiviral drug is being evaluated in a phase 3 trial called SUNRISE-3 to treat COVID-19 in outpatients at high risk for disease progression regardless of vaccination status.
  • This includes patients over 80 years of age, patients 65 years or older with at least one major risk factor, and anyone over 18 years of age who is immunocompromised, the company added.
  • AVIR +1.51% to $3.25 premarket April 25

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About AVIR

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Atea Pharmaceuticals, Inc.
Xeris Biopharma Holdings, Inc.
Nuvation Bio Inc.
Terns Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.